(NASDAQ: LYEL) Lyell Immunopharma's forecast annual revenue growth rate of 7,592.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 246.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.87%.
Lyell Immunopharma's revenue in 2024 is $130,000.On average, 1 Wall Street analysts forecast LYEL's revenue for 2024 to be $2,540,963,110, with the lowest LYEL revenue forecast at $2,540,963,110, and the highest LYEL revenue forecast at $2,540,963,110.
In 2025, LYEL is forecast to generate $2,540,963,110 in revenue, with the lowest revenue forecast at $2,540,963,110 and the highest revenue forecast at $2,540,963,110.